Literature DB >> 17661001

Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.

Ingo Roeder1, Ingmar Glauche.   

Abstract

Mathematical models and simulation studies are powerful tools to investigate dynamic properties of complex systems. Specifically, they can be used to test alternative hypotheses on underlying biological mechanisms for their consistency with real data and therefore to effectively guide the design of new experimental strategies or clinical trials. In this study, we present an overview of recently published mathematical approaches applied to the description of chronic myeloid leukemia (CML). We discuss three different fields relevant to clinical issues: the pathogenesis of the malignancy, the treatment effects of the tyrosine kinase inhibitor imatinib, and the process of acquired treatment resistance highlighting both the differences and the consistencies in the proposed hypotheses and the resulting conclusions. The mathematical models presented agree that CML can adequately be described as a clonal competition between normal and leukemic stem cells for a common resource. Furthermore, a certain therapeutic effect of imatinib on leukemic stem cells turned out to be necessary to consistently explain clinical data on the long-term response of CML patients under imatinib treatment. However, the approaches described cannot resolve the question whether or not this effect is sufficient to ultimately eradicate malignant stem cells. A number of different hypotheses have been proposed concerning the initiation and the dynamics of treatment-resistant malignant stem cell clones. The theoretical results clearly indicate that further experimental effort with the particular focus on the quantitative monitoring of resistant clones will be required to definitely distinguish between these hypotheses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661001     DOI: 10.1007/s00109-007-0241-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  62 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.

Authors:  M S Holtz; S J Forman; R Bhatia
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

3.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

Authors:  E Deutsch; A Dugray; B AbdulKarim; E Marangoni; L Maggiorella; S Vaganay; R M'Kacher; S D Rasy; F Eschwege; W Vainchenker; A G Turhan; J Bourhis
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

4.  Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Authors:  A Hochhaus; A Reiter; S Saussele; A Reichert; M Emig; J Kaeda; B Schultheis; U Berger; P C Shepherd; N C Allan; R Hehlmann; J M Goldman; N C Cross
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

5.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 6.  Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.

Authors:  E Ritchie; G Nichols
Journal:  Curr Cancer Drug Targets       Date:  2006-12       Impact factor: 3.428

7.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.

Authors:  S K Chai; G L Nichols; P Rothman
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

8.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.

Authors:  T Skorski; P Kanakaraj; M Nieborowska-Skorska; M Z Ratajczak; S C Wen; G Zon; A M Gewirtz; B Perussia; B Calabretta
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

9.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

10.  Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.

Authors:  Heather G Jørgensen; Mhairi Copland; Elaine K Allan; Xiaoyan Jiang; Allen Eaves; Connie Eaves; Tessa L Holyoake
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

View more
  8 in total

1.  Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.

Authors:  Dana Paquin; Peter S Kim; Peter P Lee; Doron Levy
Journal:  Bull Math Biol       Date:  2010-06-09       Impact factor: 1.758

2.  Characterization and quantification of clonal heterogeneity among hematopoietic stem cells: a model-based approach.

Authors:  Ingo Roeder; Katrin Horn; Hans-Bernd Sieburg; Rebecca Cho; Christa Muller-Sieburg; Markus Loeffler
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

3.  BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

Authors:  Franz X Gruber; Tuija Lundán; Rasmus Goll; Aleksandra Silye; Ingvild Mikkola; Ole Petter Rekvig; Sakari Knuutila; Kari Remes; Tobias Gedde-Dahl; Kimmo Porkka; Henrik Hjorth-Hansen
Journal:  Med Oncol       Date:  2011-01-08       Impact factor: 3.064

4.  New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.

Authors:  Ingo Roeder; Mark d'Inverno
Journal:  Blood Cells Mol Dis       Date:  2009-05-02       Impact factor: 3.039

5.  Optimizing combination therapies with existing and future CML drugs.

Authors:  Allen A Katouli; Natalia L Komarova
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

6.  Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.

Authors:  Stefan Balabanov; Artur Gontarewicz; Gunhild Keller; Laura Raddrizzani; Melanie Braig; Roberta Bosotti; Jürgen Moll; Edgar Jost; Christine Barett; Imke Rohe; Carsten Bokemeyer; Tessa L Holyoake; Tim H Brümmendorf
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

7.  Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma.

Authors:  Hermann B Frieboes; Bryan R Smith; Zhihui Wang; Masakatsu Kotsuma; Ken Ito; Armin Day; Benjamin Cahill; Colin Flinders; Shannon M Mumenthaler; Parag Mallick; Eman Simbawa; A S Al-Fhaid; S R Mahmoud; Sanjiv S Gambhir; Vittorio Cristini
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

8.  Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.

Authors:  Clemens Woywod; Franz X Gruber; Richard A Engh; Tor Flå
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.